Case-Based Roundtable

At a recent Dermatology Times Case-Based Roundtable event, Andrew Baker, PA-C, MBA, explored the management of skin cancers with GEP testing through 4 complex cases.

An expert discusses how prurigo nodularis represents one of the most severe itching conditions in dermatology, significantly impacting patients' quality of life and sleep, and explains the importance of breaking the itch-scratch cycle while highlighting recent treatment advances with targeted biologics like dupilumab and nemolizumab.

At a recent Dermatology Times Case-Based Roundtable event, Michael Gold, MD, explored innovative vitiligo treatment strategies through complex cases and emerging therapies.

At a recent Dermatology Times Case-Based Roundtable event, Lisa Swanson, MD, discussed 3 diverse atopic dermatitis patient cases.

The significance of patient education and setting realistic expectations for the often-slow process of repigmentation in vitiligo treatment was a key focus of the discussion.

John Strasswimmer, MD, PhD, spoke on the difficulty of managing adverse effects, the role of interdisciplinary clinical relationships, and the challenges in complex and older patients.

The expert discussion focused on patient management strategies, treatment modalities, and the role of multidisciplinary collaboration.

Serota and other field experts discussed best practices as well as new therapeutics.

At a recent Dermatology Times Case-Based Roundtable event, James Q. Del Rosso, DO, discussed the limitations of topical corticosteroids and the benefits of nonsteroidals.

Nonsteroidal AD therapies are gaining attention due to their rapid effectiveness and ability to offer an alternative to long-term steroid use.

Adelaide A. Hebert, MD, FAAD, stressed the importance of educating patients, setting realistic expectations, and ensuring they adhere to AD treatment plans.

Alexandra Golant, MD, led a Dermatology Times Case-Based Roundtable® event that focused on advancing therapeutic strategies for atopic dermatitis.

New drugs targeting IL-4, IL-13, and IL-31 pathways provide options for tailored eczema treatments.

Lisa Weiss, MMSc, PA-C, and colleagues offered insights on managing severe atopic dermatitis cases with biologics, nonsteroidal treatments, and strategies for addressing physical and emotional impacts.

A recent expert discussion highlighted the importance of long-term planning, including when and how to adjust or transition therapies.

Tina Bhutani-Jacques, MD, highlighted the importance of individualized and informative care while building trust among patients and caregivers.